Dr. Joseph Kaempf shares data from a systematic review and meta-analysis on whether neurodevelopment outcomes are changing over time in extremely premature infants #HotTopicsNeo2020#neoEBM
The objective of the review was to evaluate within NICU or within cohort trends in NDI over time
A total of 13 studies were included in analysis
Summary of findings from the various studies with trends in NDI over time by year of birth
No evidence of a significant change in NDI rate over time, with an average NDI rate of 36% at the first time point
Here are the conclusions regarding the findings from the meta-analysis
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Next up in "New Approaches to Cooling" Deirdre Murray of @CUH_Cork discussing “Neurodevelopmental Outcomes after Mild HIE.” Read more about Prof. Murray and her work: infantcentre.ie/who-we-are-2/o…
How do infants with different HIE severity grades perform on IQ testing at 5 years of age? Summary from: pubmed.ncbi.nlm.nih.gov/27650049/, which includes additional outcomes measures.
Take home point: mild and moderate HIE infants similar.
Reese: Talk to focus on steroid use. To begin, what postnatal steroids are we using? Dexamethasone and hydrocortisone most common systematic exposures, budenoside most common inhaled exposure.
Next up in #HotTopicsNeo2020: Erik Jensen of @ChildrensPhila discussing how the baseline risk of BPD impacts the number needed to treat when considering effective therapies.
Presentation builds on recently published report in @JPediatr: drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat jpeds.com/article/S0022-…
What is the earliest gestational age, assuming dating is correct, where you (or your hospital) routinely offer active postnatal resuscitation if desired by the family
If an infant at 22-24 weeks GA has evidence of inadequate organ perfusion (low urine output, decreasing BP), what is your first line treatment:
First up in: "Pharmacotherapy for BPD: We Know Less than We Think We Do" at #HotTopicsNeo2020 is Dr. Gerri Baer (@thegerribaer), Team Leader for Neonatology @US_FDA, discussing "Challenges in Studying Drugs for BPD" @HotTopicsNeo#neoEBM
Baer: no (zero, zilch, none!) drugs approved in the USA to prevent or treat BPD.
Highlights various cohorts demonstrating the ongoing high burden of BPD:
Baer: broad view of challenges to BPD Rx, illustrated by 3 buckets: understanding phenotypes/endotypes, definitions and classification and choosing adequate endpoints. #HotTopicsNeo2020@HotTopicsNeo